<?xml version="1.0" encoding="UTF-8"?>
<ref id="B24">
 <label>24</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Locke</surname>
    <given-names>FL</given-names>
   </name>
   <name>
    <surname>Ghobadi</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Jacobson</surname>
    <given-names>CA</given-names>
   </name>
   <name>
    <surname>Miklos</surname>
    <given-names>DB</given-names>
   </name>
   <name>
    <surname>Lekakis</surname>
    <given-names>LJ</given-names>
   </name>
   <name>
    <surname>Oluwole</surname>
    <given-names>OO</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial</article-title>. 
  <source>Lancet Oncol</source> (
  <year>2019</year>) 
  <volume>20</volume>(
  <issue>1</issue>):
  <fpage>31</fpage>–
  <lpage>42</lpage>.  
  <pub-id pub-id-type="doi">10.1016/S1470-2045(18)30864-7</pub-id>
  <pub-id pub-id-type="pmid">30518502</pub-id>
 </mixed-citation>
</ref>
